X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1277) 1277
Publication (97) 97
Book / eBook (26) 26
Book Chapter (15) 15
Book Review (15) 15
Newspaper Article (12) 12
Newsletter (5) 5
Magazine Article (2) 2
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1125) 1125
female (675) 675
male (620) 620
index medicus (574) 574
middle aged (549) 549
aged (503) 503
oncology (495) 495
gallbladder neoplasms - drug therapy (487) 487
cancer (415) 415
gallbladder (384) 384
gallbladder neoplasms - pathology (368) 368
chemotherapy (348) 348
adult (338) 338
gallbladder cancer (326) 326
antineoplastic combined chemotherapy protocols - therapeutic use (238) 238
deoxycytidine - analogs & derivatives (235) 235
treatment outcome (226) 226
gemcitabine (220) 220
surgery (199) 199
prognosis (193) 193
carcinoma (192) 192
biliary tract neoplasms - drug therapy (182) 182
aged, 80 and over (181) 181
gallbladder carcinoma (176) 176
animals (171) 171
gallbladder neoplasms - surgery (166) 166
cholangiocarcinoma (161) 161
deoxycytidine - administration & dosage (160) 160
cell line, tumor (156) 156
tumors (151) 151
research (149) 149
metastasis (142) 142
cisplatin (141) 141
care and treatment (139) 139
adenocarcinoma - drug therapy (136) 136
gastroenterology & hepatology (134) 134
bile duct neoplasms - drug therapy (130) 130
neoplasm staging (130) 130
antineoplastic agents - therapeutic use (128) 128
fluorouracil - administration & dosage (113) 113
biliary tract cancer (112) 112
cancer therapies (112) 112
medical prognosis (112) 112
cisplatin - administration & dosage (111) 111
health aspects (111) 111
5-fluorouracil (108) 108
survival (107) 107
cholangiocarcinoma - drug therapy (105) 105
retrospective studies (105) 105
gallbladder diseases (103) 103
mice (102) 102
phase-ii trial (102) 102
apoptosis (99) 99
expression (99) 99
medicine & public health (99) 99
survival analysis (95) 95
biliary tract neoplasms - pathology (94) 94
liver neoplasms - drug therapy (94) 94
survival rate (93) 93
gallbladder neoplasms - metabolism (91) 91
patients (90) 90
analysis (88) 88
proteins (88) 88
gallbladder neoplasms - mortality (87) 87
combined modality therapy (84) 84
disease-free survival (84) 84
antineoplastic combined chemotherapy protocols - adverse effects (82) 82
drug administration schedule (82) 82
studies (82) 82
gallbladder neoplasms - genetics (81) 81
risk factors (81) 81
therapy (81) 81
deoxycytidine - therapeutic use (80) 80
drug therapy (79) 79
cell proliferation - drug effects (78) 78
cholecystectomy (78) 78
liver neoplasms - secondary (77) 77
medicine (77) 77
apoptosis - drug effects (76) 76
liver (76) 76
chemotherapy, adjuvant (75) 75
pathology (75) 75
antimetabolites, antineoplastic - therapeutic use (73) 73
pharmacology & pharmacy (73) 73
bile duct neoplasms - pathology (72) 72
gene expression (71) 71
kinases (69) 69
research article (69) 69
adenocarcinoma - pathology (66) 66
capecitabine (66) 66
gallbladder neoplasms - therapy (66) 66
mice, nude (66) 66
neoplasms. tumors. oncology. including cancer and carcinogens (66) 66
cancer research (65) 65
hepatocellular-carcinoma (65) 65
phase-ii (64) 64
tomography, x-ray computed (64) 64
adenocarcinoma (63) 63
combination (63) 63
liver cancer (63) 63
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1172) 1172
Japanese (104) 104
German (19) 19
Spanish (11) 11
French (10) 10
Chinese (9) 9
Italian (7) 7
Hungarian (2) 2
Czech (1) 1
Danish (1) 1
Korean (1) 1
Russian (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 181 - 188
Summary Background Combination chemotherapy with gemcitabine and a platinum-based agent is regarded as a standard treatment for patients with advanced... 
Hematology, Oncology and Palliative Medicine | PLUS GEMCITABINE | CHOLANGIOCARCINOMA | CISPLATIN | ONCOLOGY | ADENOCARCINOMA | PANCREATIC-CANCER | CLINICAL-TRIALS | II TRIAL | COMBINATION | CHEMOTHERAPY | GALL-BLADDER CANCER | Erlotinib Hydrochloride | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Deoxycytidine - therapeutic use | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Gallbladder Neoplasms - epidemiology | Cholangiocarcinoma - epidemiology | Deoxycytidine - administration & dosage | Biliary Tract Neoplasms - epidemiology | Disease Progression | Disease-Free Survival | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Gallbladder Neoplasms - pathology | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Medical colleges | Chemotherapy | Erlotinib | Gemcitabine | Pancreatic cancer | Oncology, Experimental | Clinical trials | Research | Drug therapy, Combination | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 819 - 828
Summary Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | MULTICENTER | CISPLATIN | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | GALLBLADDER | COMBINATION | TUMORS | CHEMOTHERAPY | GALL-BLADDER CANCER | ras Proteins - genetics | Peripheral Nervous System Diseases - chemically induced | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Alanine Transaminase - blood | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Oxaliplatin | Common Bile Duct Neoplasms - drug therapy | Adult | Bile Ducts, Intrahepatic | Female | Bile Duct Neoplasms - genetics | Cetuximab | Neutropenia - chemically induced | Common Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Aspartate Aminotransferases - blood | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Cholangiocarcinoma - genetics | Carcinoma - genetics | Aged | Mutation | Deoxycytidine - analogs & derivatives | Chemotherapy | Product development | Gemcitabine | Comparative analysis | Cancer
Journal Article
Cancer, ISSN 0008-543X, 10/2002, Volume 95, Issue 8, pp. 1685 - 1695
BACKGROUND. To the authors' knowledge, the significance of postoperative adjuvant chemotherapy in pancreaticobiliary carcinoma has not yet been clarified. A... 
Adjuvant chemotherapy | Pancreatic carcinoma | Bile duct carcinoma | Disease-free survival | Carcinoma of the ampulla of Vater | Survival | Gallbladder carcinoma | BILIARY CARCINOMA | adjuvant chemotherapy | bile duct carcinoma | MITOMYCIN-C | ADENOCARCINOMA | survival | PANCREAS | P53 PROTEIN IMMUNOREACTIVITY | RADIATION-THERAPY | carcinoma of the ampulla of Vater | 5-FLUOROURACIL | EXTRAHEPATIC BILE-DUCT | CANCER-PATIENTS | pancreatic carcinoma | disease-free survival | ONCOLOGY | gallbladder carcinoma | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Pancreatic Neoplasms - drug therapy | Fluorouracil - administration & dosage | Common Bile Duct Neoplasms - drug therapy | Adult | Female | Common Bile Duct Neoplasms - surgery | Chemotherapy, Adjuvant | Mitomycins - administration & dosage | Bile Duct Neoplasms - drug therapy | Bile Duct Neoplasms - surgery | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - surgery | Neoplasm Recurrence, Local | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Gallbladder Neoplasms - pathology | Bile Duct Neoplasms - pathology | Infusions, Intravenous | Common Bile Duct Neoplasms - pathology | Gallbladder Neoplasms - surgery | Evaluation | Drug therapy | Postoperative care | Gallbladder cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2015, Volume 33, Issue 24, pp. 2617 - 2622
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2010, Volume 102, Issue 1, pp. 68 - 72
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 18, pp. 3125 - 3135
Abstract Background Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC)... 
Hematology, Oncology and Palliative Medicine | Advanced biliary tract cancer | BTC | PDGFRβ | Hif1α | VEGFR-3 | c-kit | Sorafenib | VEGFR-2 | Hand-foot syndrome | ADVANCED HEPATOCELLULAR-CARCINOMA | CHOLANGIOCARCINOMA | COMBINATION THERAPY | GALLBLADDER CARCINOMA | OPEN-LABEL | OXALIPLATIN | Hif1 alpha | TRIAL | SKIN TOXICITY | ONCOLOGY | PDGFR beta | ADVANCED GASTRIC-CANCER | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Prospective Studies | Humans | Middle Aged | Male | Hand-Foot Syndrome - etiology | Phenylurea Compounds - adverse effects | Biliary Tract Neoplasms - metabolism | Gallbladder Neoplasms - metabolism | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Bile Ducts, Intrahepatic | Deoxycytidine - adverse effects | Female | Biliary Tract Neoplasms - drug therapy | Bile Duct Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Bile Duct Neoplasms - metabolism | Double-Blind Method | Drug Administration Schedule | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Niacinamide - adverse effects | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Chemokine CXCL12 - metabolism | Gallbladder Neoplasms - drug therapy | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Vascular Endothelial Growth Factors - metabolism | Aged | Gallbladder Neoplasms - pathology | Bile Duct Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Research | Gemcitabine | Oncology, Experimental | Cancer
Journal Article
Gastroenterology, ISSN 0016-5085, 2008, Volume 135, Issue 4, pp. 1358 - 1368.e4
Journal Article
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 3/2011, Volume 18, Issue 3, pp. 651 - 658
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2013, Volume 109, Issue 4, pp. 915 - 919
Journal Article
Journal Article
Journal Article